Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial.

[1]  F. Becce,et al.  Reliability and Diagnostic Accuracy of Radiography for the Diagnosis of Calcium Pyrophosphate Deposition: Performance of the Novel Definitions Developed by an International Multidisciplinary Working Group , 2022, Arthritis & rheumatology.

[2]  F. Salaffi,et al.  In patients with acute mono-oligoarthritis, a targeted ultrasound scanning protocol shows great accuracy for the diagnosis of gout and CPPD. , 2022, Rheumatology.

[3]  D. Solomon,et al.  Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis , 2022, Annals of the Rheumatic Diseases.

[4]  F. Becce,et al.  Identifying Potential Classification Criteria for Calcium Pyrophosphate Deposition Disease: Item Generation and Item Reduction , 2021, Arthritis care & research.

[5]  F. Salaffi,et al.  The diagnostic value of conventional radiography and musculoskeletal ultrasonography in calcium pyrophosphate deposition disease: a systematic literature review and meta-analysis. , 2021, Osteoarthritis and cartilage.

[6]  A. Rosenthal,et al.  Management of calcium pyrophosphate crystal deposition disease: A systematic review. , 2020, Seminars in arthritis and rheumatism.

[7]  D. Nunan,et al.  Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care , 2019, Annals of the rheumatic diseases.

[8]  G. Mccarthy,et al.  Calcium crystal deposition diseases — beyond gout , 2018, Nature Reviews Rheumatology.

[9]  R. Terkeltaub,et al.  Review: Unmet Needs and the Path Forward in Joint Disease Associated With Calcium Pyrophosphate Crystal Deposition , 2018, Arthritis & rheumatology.

[10]  A. Iagnocco,et al.  The predictive role of ultrasound-detected tenosynovitis and joint synovitis for flare in patients with rheumatoid arthritis in stable remission. Results of an Italian multicentre study of the Italian Society for Rheumatology Group for Ultrasound: the STARTER study , 2018, Annals of the rheumatic diseases.

[11]  A. Wongrakpanich,et al.  A Comprehensive Review of Non-Steroidal Anti-Inflammatory Drug Use in The Elderly , 2018, Aging and disease.

[12]  P. Richette,et al.  Colchicine in Gout: An Update. , 2018, Current pharmaceutical design.

[13]  P. Dieudé,et al.  Comparison of ultrasonography and radiography of the wrist for diagnosis of calcium pyrophosphate deposition. , 2017, Joint, bone, spine : revue du rhumatisme.

[14]  A. Rosenthal,et al.  Calcium Pyrophosphate Deposition Disease. , 2016, The New England journal of medicine.

[15]  A. Abhishek.  Calcium pyrophosphate deposition disease: a review of epidemiologic findings , 2016, Current opinion in rheumatology.

[16]  T. Rainer,et al.  Oral Prednisolone in the Treatment of Acute Gout: A Pragmatic, Multicenter, Double-Blind, Randomized Trial. , 2016, Annals of internal medicine.

[17]  M. Maravic,et al.  Hospital burden of gout, pseudogout and other crystal arthropathies in France. , 2015, Joint, bone, spine : revue du rhumatisme.

[18]  Robert R Borsheski,et al.  Pain management in the geriatric population. , 2014, Missouri medicine.

[19]  P. Guerne,et al.  Methotrexate in chronic-recurrent calcium pyrophosphate deposition disease: no significant effect in a randomized crossover trial , 2014, Arthritis Research & Therapy.

[20]  S. Wason,et al.  Effect of Steady-State Atorvastatin on the Pharmacokinetics of a Single Dose of Colchicine in Healthy Adults Under Fasted Conditions , 2014, Clinical Drug Investigation.

[21]  R. Terkeltaub,et al.  Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. , 2011, Arthritis and rheumatism.

[22]  B. Leeb,et al.  EULAR recommendations for calcium pyrophosphate deposition. Part II: Management , 2011, Annals of the rheumatic diseases.

[23]  R. Terkeltaub,et al.  High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. , 2010, Arthritis and rheumatism.

[24]  C. Weel,et al.  Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial , 2008, The Lancet.

[25]  P. Cameron,et al.  Comparison of Oral Prednisolone/Paracetamol and Oral Indomethacin/Paracetamol Combination Therapy in the Treatment of Acute Goutlike Arthritis: A Double-Blind, Randomized, Controlled Trial , 2007, Annals of Emergency Medicine.

[26]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[27]  S. Pocock,et al.  Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. , 2006, JAMA.

[28]  B. Rothschild,et al.  Evidence for an effect of hydroxychloroquine in chronic pyrophosphate deposition disease. , 1996, Journal of clinical rheumatology.

[29]  T. Vischer,et al.  Corticosteroid therapy for the treatment of acute attacks of crystal-induced arthritis: an effective alternative to nonsteroidal antiinflammatory drugs. , 1996, Revue du rhumatisme.

[30]  K. Todd,et al.  Clinical significance of reported changes in pain severity. , 1996, Annals of emergency medicine.

[31]  G. Ho,et al.  Gout and pseudogout in hospitalized patients. , 1993, Archives of internal medicine.

[32]  A. Alvarellos,et al.  Colchicine prophylaxis in pseudogout. , 1986, The Journal of rheumatology.

[33]  N. A. Cummings,et al.  Intravenous colchicine in the treatment of acute pseudogout. , 1980, Arthritis and rheumatism.

[34]  L. Simchowitz,et al.  Colchicine and pseudogout. , 1980, Arthritis & Rheumatism.